CRYOABLATION FOR
BONE METASTASES
Percutaneous image-guided cryoablation destroys painful bone lesions and deactivates periosteal nerve fibres — providing durable local control and pain relief without additional radiation exposure.
analyticsAt a Glance
- check_circleFreezes bone metastases to –40°C or below using argon-gas cryoprobes under CT or MRI guidance
- check_circleDemonstrated >70% pain response rate in RCTs including the MOTION trial
- check_circlePalliative and curative-intent roles: spine, pelvis, long bones, and rib lesions
- check_circleAccessible at specialist interventional oncology centres in China and India via CancerFax
Why Cryoablation Is Used for Bone Metastases
Bone metastases affect up to 70% of patients with advanced breast, prostate, lung, and kidney cancers. Pain from periosteal nerve involvement is often refractory to systemic therapy alone, and repeat radiation is limited by cumulative dose constraints.
“Cryoablation does not just destroy tumour tissue — it simultaneously silences the periosteal nerve fibres responsible for bone pain.”
Dual Mechanism of Action
Ice-ball formation at –40°C or below destroys tumour cells directly, while the extreme cold deactivates periosteal pain fibres — producing both local control and analgesic effect in a single procedure.
When It Is Indicated
Preferred for oligometastatic bone disease, lesions refractory to radiotherapy, patients ineligible for re-irradiation, and cases where tissue diagnosis is needed alongside palliation.
Key Clinical Numbers
The MOTION trial and subsequent studies have established cryoablation as a first-line palliative ablation option for painful bone metastases.
- >70%Pain response rateReported in the MOTION trial at 3 months for painful bone metastases treated with cryoablation.
- –40°CMinimum lethal temperatureTemperatures below –40°C reliably achieve complete tumour cell necrosis within the ice-ball margin.
- 3–5 cmTypical treatable lesion sizeMost bone metastases amenable to percutaneous cryoablation fall within this size range with a single freeze–thaw cycle.
- 1 hrApproximate procedure timeMost single-lesion bone cryoablation procedures are completed within 45–75 minutes under CT guidance.
How a Bone Cryoablation Procedure Is Performed
The procedure is minimally invasive and typically performed under CT or MRI guidance with local anaesthesia and conscious sedation.
- 1
Pre-Procedure Imaging
CT or MRI confirms lesion location, adjacent neurovascular structures, and optimal probe trajectory to plan a safe approach.
- 2
Probe Placement
One or more cryoprobes are inserted percutaneously through the skin directly into the bone lesion under real-time CT fluoroscopy guidance.
- 3
Active Freeze Cycle
Argon gas circulates through the probe, cooling the tip to –150°C and forming a visible ice-ball that encompasses the target lesion with a safety margin.
- 4
Passive Thaw
The ice-ball is allowed to passively thaw, maximising cell disruption through osmotic stress before the second freeze cycle.
- 5
Second Freeze Cycle
A second active freeze is applied to ensure the entire tumour volume — including the peripheral margin — has been exposed to lethal temperatures.
- 6
Probe Removal and Recovery
Probes are removed and patients are monitored for 2–4 hours. Most are discharged the same day or after an overnight stay.
Benefits vs Limitations
Cryoablation is a well-evidenced option for bone pain palliation, but patient selection and lesion geometry determine suitability.
Benefits
- Durable pain reliefOver 70% of patients achieve meaningful pain reduction sustained at 3 months — comparable or superior to external beam radiotherapy in RCT data.
- No additional radiation doseCritical advantage for patients who have already received palliative radiotherapy to the same site and face re-irradiation dose constraints.
- Simultaneous biopsy and treatmentCore needle biopsy can be performed through the same access site at the time of cryoablation — obtaining histology and treating in one session.
- Immune stimulation potentialCryoablation releases tumour antigens in an immunogenic context, potentially augmenting response to concurrent checkpoint inhibitor therapy.
Limitations
- Proximity to spinal cordLesions abutting the spinal canal require advanced nerve monitoring and hydrodissection techniques; not all centres have this capability.
- Limited to oligometastatic diseaseCryoablation treats individual lesions — it does not address diffuse polyosseous disease, which requires systemic therapy.
- Pathological fracture riskLarge lytic lesions in weight-bearing bones may require concurrent cementoplasty or prophylactic fixation to prevent post-procedure fracture.
- Imaging interpretation skillAccurate ice-ball margin assessment on CT requires experienced operators — incomplete ablation is the primary cause of local recurrence.
Clinical Efficacy: Key Trial Outcomes
Prospective and randomised trial data support cryoablation as a primary palliative ablation modality for bone metastases.
MOTION Trial (Callstrom et al., JVIR 2013)
Source: Callstrom MR et al., J Vasc Interv Radiol. 2013;24(8):1085–1092
- Worst pain score reduction ≥2 points at Day 867%
- Worst pain score reduction ≥2 points at Day 5773%
- Analgesic reduction or stable use58%
Cryoablation vs Radiotherapy (Goetz et al., Radiology 2004)
Source: Goetz MP et al., Radiology. 2004;230(2):596–601
- Pain reduction: cryoablation arm80%
- Pain reduction: external beam RT arm66%
- Complete pain relief: cryoablation arm47%
Cryoablation by Lesion Site — Clinical Considerations
Site-specific factors guide probe selection, safety measures, and expected outcomes for bone cryoablation.
| Site | Typical Approach | Key Consideration | Adjunct Required? |
|---|---|---|---|
| Spine (vertebral body) | CT-guided transpedicular or paracostal | Spinal cord proximity — thermosensor placement required | Thermosensor + hydrodissection |
| Pelvis / sacrum | CT-guided direct percutaneous | Large vessel proximity; wide ice-ball needed | Cementoplasty if lytic |
| Long bone (femur, humerus) | CT or fluoroscopy-guided | Weight-bearing status; fracture risk assessment | Prophylactic fixation if >50% cortex involved |
| Rib lesion | CT-guided direct or intercostal | Pleural space proximity; pneumothorax risk | Post-procedure chest X-ray |
| Acetabulum | CT-guided percutaneous | Hip joint integrity; load-bearing implications | Cementoplasty in majority of cases |
More from the Cryoablation Therapy Resource Library
Continue exploring cryoablation — from the complete treatment overview to disease-specific evidence and combination strategies.
- Cryoablation Therapy — Complete Treatment Guide
- Cryoablation for Liver Tumours: HCC and Metastases
- Cryoablation for Lung Cancer and Pulmonary Lesions
- Cryoablation for Breast Cancer and Breast Fibroadenoma
- Cryoimmunotherapy: Combining Cryoablation with Checkpoint Inhibitors
- Cryoablation for Kidney Cancer: Renal Cell Carcinoma
Frequently Asked Questions
Common questions from patients and families considering cryoablation for bone metastasis pain.
About the Procedure
How quickly does pain relief begin after cryoablation?
Many patients notice pain reduction within 24–72 hours of the procedure, with maximum benefit typically reached by Day 8–14. The MOTION trial reported that two-thirds of patients achieved meaningful pain score reduction within the first week.
Can cryoablation be repeated if the lesion recurs locally?
Yes. One of the practical advantages of cryoablation over radiotherapy is that there is no cumulative dose limit — the same lesion can be re-treated if imaging shows local progression, and a new lesion at a different site can be treated independently without impacting prior treatment sites.
Is cryoablation of the spine safe?
Spinal cryoablation requires additional safeguards: temperature sensors placed in the spinal canal and epidural space monitor real-time temperature during freezing, and hydrodissection with saline can displace the ice-ball away from the cord. Centres experienced in spinal ablation achieve low complication rates, but this procedure should only be performed by trained interventional oncologists or neuroradiologists.
Will I need to stop my bone-targeted therapy before cryoablation?
Bisphosphonates and denosumab are generally continued — they do not interfere with cryoablation. Your oncologist will review systemic therapy, particularly antiangiogenics like bevacizumab, which may be paused briefly due to wound healing considerations. Discuss the full medication list with the treating team before the procedure.
Access and Costs
Where is cryoablation for bone metastases available in China and India?
Major interventional oncology units at Chinese academic medical centres — including those affiliated with Peking Union Medical College and Sun Yat-sen University Cancer Center — perform bone cryoablation routinely. In India, Apollo Hospitals and Tata Memorial Centre have dedicated ablation programmes. CancerFax coordinates referrals and pre-procedure consultations at vetted centres in both countries.
How does cryoablation compare in cost to radiotherapy for bone pain?
In China, a single-lesion bone cryoablation session typically costs USD 2,500–6,000 depending on the hospital tier and lesion complexity — compared to USD 3,000–8,000 for a palliative EBRT course at the same institutions. In Western centres, cryoablation may cost USD 15,000–30,000 per session. Contact CancerFax for a personalised cost estimate based on your lesion and location.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could Cryoablation Relieve Your Bone Pain?
CancerFax reviews your imaging and bone metastasis profile to assess whether cryoablation is appropriate for your lesion location, size, and systemic treatment status — then connects you with qualified interventional oncologists in China or India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.